Tuesday, 12th November Clinical Oncology Society of Australia Annual Scientific Meeting 2019

There is international momentum for focused efforts to improve care and outcomes for older people with cancer, including international Guidelines. This breakfast session aims to promote discussion from consumer, clinician, service and policy lens about what needs to change to improve outcomes for older people with Cancer in the Australian setting

Chair: Tim To 
Speakers: Dr Jonathon Hogan-Doran – Medical oncologist, Royal Adelaide Hospital, Dr Anna Mislang – Medical oncologist, Adelaide Cancer Centre, Dr Phil Haywood – Health economist, University of Technology Sydney, Peter Jenkin – Nurse practitioner, Resthaven residential aged care, Rebecca Drake – Nurse, Royal Adelaide Hospital Geriatric Oncology, Prof David Roder – Epidemiologist, University of South Australia, Consumer – TBC  

Genetic testing in women with ovarian cancer or triple negative breast cancer is accepted, available and usually Medicare funded. Why is it not more common in men? We know men with metastatic prostate cancer, unselected by age or family history, have >10% chance of carrying a germline mutation in a homologous repair (HR) gene, with BRCA2 making up 66%. This has important implications for patients. Prostate cancers containing BRCA2 mutations have been shown to be uniquely aggressive. The PSA velocity in these men is unreliable making aggressive treatment rather than active surveillance the initial treatment of choice. Men with BRCA2 mutations and metastatic disease demonstrate high response rates to PARP inhibitors and platinum-based chemotherapy. And, for men with mutations in mismatch repair genes, such as in Lynch syndrome, the tumours are highly immunogenic. So, when should you consider genetic testing, what test to choose and what will the test tell you? international guidelines such as NCCN’s state “germline genetic testing [BRCA1, BRCA2, ATM and PALB2] should be considered in all men with high risk or metastatic prostate cancer” as well as screening for Lynch syndrome [MLH1, MSH2, MSH6, PMS2] “at diagnosis of castration resistant prostate cancer”. How does that translate into the Australian setting? This practical session will explain how to interpret somatic (tumour based) testing, whether ordered in the clinic or via a research trial. You will learn when germline (hereditary) testing should be performed and the implications for patients and their blood relatives. Using case studies, we will demonstrate how genetic testing is affordable and accessible and guides treatment decisions in men with prostate cancer, at all stages of their disease.

Speaker: Dr Hilda High, Genetic Oncologist Head of Sydney Cancer Genetics
Chairperson: Dr Gerald Goh, Senior Regional Segment Marketing Manager, Oncology Illumina Asia Pacific Japan

Welcome by COSA President, Nick Pavlakis

Welcome to Country by local indigenous group

Official opening by His Excellency the Honourable Hieu Van Le AC, Governor of South Australia

• Latest developments in prostate cancer surgery and active surveillance  - Stacy Loeb
• Precise and Personalised: Radiation Therapy for Prostate Cancer in 2019 - Sandra L Turner
• Metastatic hormone-sensitive prostate cancer: A new era  - Arun Azad
• Supportive care for men with prostate cancer  - Patsy Yates

10:05 AM Panel Discussion

• Biopsychosocial Screening: The Bridge to Engagement, Patient Experience and Partnerships  - Matthew Loscalzo
• Ten-year quality of life outcomes in men with prostate cancer  - Nicholas F Ralph
• Emotional care needs of prostate cancer survivors and their partners: what do we know?  - Peter 'Kevin' O'Shaughnessy
• Survivorship care plans for prostate cancer survivors – describing the Australian landscape - Nadia Corsini

12:20 PM Panel Discussion

• Patient selection and dose prescription for radiation therapy  - Marcus Dreosti
• Patient selection for palliative chemotherapy  - Sina Vatandoust
• Renal function estimates vs measurements; implications for chemotherapy dosing  - Jenny Casanova
• Renal-oncology; impacts of these treatments on renal health  - Rob Carroll

• Computed tomography-defined sarcopenia negatively impacts overall survival in patients with head and neck cancer – implications for practice  - Merran Findlay
• Nutrition and eHealth - Marina Reeves
• Can early and intensive nutrition care delivered via digital platform or telephone improve quality of life in patients with upper gastrointestinal cancer? - Lauren Hanna
• Nutrition and Exercise Interventions for Prostate Cancer - Brenton J Baguley

12:20 PM Panel Discussion

• Cancer Care 2040 – meeting the global demand - Michael Barton
• Cancer and Equality- The Global view - Lena Sharp
• Impact of environmental changes on cancer  - Hubertus Jersmann

2:30PM Panel Discussion - Michael Barton OAM, Lena Sharp, Hubertus Jersmann, Sanchia Aranda

• Antibiotic-induced depletion of gut microbiota: impact on radiation-induced oral mucositis in rats - Ghanyah Al-Qadami
• Do we have a Black Cat in a Dark Room? - Looking for patient data in cancer research    - Michelle Foong
• Empowering adolescents and young adults with cancer (AYAs) and their families in shared decision-making: Qualitative findings from interviews with healthcare professionals - Ilona Juraskova
• Development and analytical validation of a 523-gene assay for cell-free DNA  - Gerald Goh
• Novel human cancer cell-line genomic model using CRISPR/Cas9 for assessing methotrexate pharmacogenomics: MiSSK Study – Phase I - Zeyad Ibrahim
• Systematic review (SR) of methotrexate pharmacogenomics in the treatment of paediatric cancers: Evidence and Gap - Zeyad Ibrahim
• Metabolic, cardiovascular and bone health in women with early stage breast cancer before and during cancer treatment - Bogda Koczwara
• The gut microbiome as an intervention target for neratinib-induced diarrhea - Joanne Bowen
• Intestinal microbiome and chemotherapy-induced neutropenia - Michael Thomsen
• A review on quality of life in pancreatic cancer - Clare Toms
• The use of honey and bee products in the prevention and treatment of oral mucositis in cancer patients – a systematic review. - Kellie Toohey
•  Improved Gut integrity in female breast cancer survivors after a 12-week exercise intervention. - Kellie Toohey
• PanSupport: A unique Australian supportive care web-app designed with and for people affected by pancreatic cancer. - Mei Krishnasamy
• Next generation audit and feedback: findings of a systematic review and interviews with international thought leaders - Candice Donnelly
• Development of a quality of care dashboard in breast cancer using EHR data - Candice Donnelly
• The needs and preferences of men living with metastatic prostate cancer regarding a web-based exercise prescription and education tool: A qualitative study - Holly E Evans
• Developing an Online Healthy Living Program - Ashley R Grant
• Access and engagement disparities in digital health in cancer care: stakeholder views on age and other contributing factors - Emma Kemp
• Regional and metropolitan patients have similar attitudes about using smartphone-delivered healthcare in the routine setting  - Richard C Khor
• WeCan: Refresh of the Victorian Supportive Care in Care resources - Mei Krishnasamy
• Development and Proof-of-Concept Trial of a Smartphone-Based Program to Support Oral Chemotherapy Adherence in Young and Adult Cancer Patients - Xiomara Skrabal Ross
• Review of real-world demographic trends and engagement in smartphone-based collection of patient reported outcomes - Daniel Tian
• ¹⁷⁷Lu-PSMA-617 as monotherapy or in combination with NOX66 for the treatment of men with late-stage metastatic castrate resistant prostate cancer (mCRPC): An exploratory analysis. - Luke Ardolino
• Prostate Cancer Extent of Disease, Treatment Utilisation and Survival: The impact of Culturally and Linguistically Diverse (CALD) Status, in South West Sydney Local Health District (SWSLHD) - Angela Berthelsen
• Acceptability of wearable activity trackers for physical activity and sedentary behavior in daily clinical practice in men with prostate cancer - Renée Bultijnck
• A comparative study of physical activity levels and sedentary behavior patterns between disease stages of prostate cancer patients - Renée Bultijnck
• ⁶⁸Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer after definitive treatment: an Australian prospective study. - Amy Davies
• Prostate Cancer outcome disparity in South West Victoria - Samantha L Dean
• Retrospective evaluation of radiation therapy planning margins for patients undergoing radical radiation therapy treatment for bladder cancer using Volumetric Modulated Arc Therapy - Kath Dower
• A pilot study to evaluate the feasibility and efficacy of high dose weekly radiotherapy for treating large or fungating inguinal nodes in advanced Penile cancers - Subhash Gupta
• Treatment combinations among prostate cancer patients diagnosed in the Loddon Mallee region - Michael Leach
• Optimum Surgical Utilization Rates for Urological Cancers in Australia - Sathira K Perera
• Muscle invasive (MIBC) and metastatic (mBC) Urothelial cancer: modern treatment practices and clinical outcomes in Victoria   - Phuong Phan
• Cytology-based Circulating-Tumour-Cell (CTC) Screening Test improves Detection of Prostate Cancer - Karin Ried
• What is the participant experience of a clinical trial? Insights from a qualitative study with GU patients - Natasha Roberts
• PROfound: Phase III study of the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair gene mutations (HRRm) - Shahneen Sandhu
• Apalutamide and Overall Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Updated Results From the Phase 3 SPARTAN Study - Thean Hsiang Tan
• Physical activity and the risk of non-Hodgkin lymphoma subtypes - Terry Boyle
• Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis - Yun Megan Foo
• Global patterns in the incidence of acral melanoma: systematic review and meta-analysis - Yun Megan Foo
• Management of Neuroendocrine tumours in metropolitan and regional South West Victoria - Samantha L Dean
• Has the transition to digital mammography in breast cancer screening resulted in real benefits? - Kristen Pickles
• Factors Influencing Recurrence of Stage I-III Rectal Cancer in Regional Australia - Lucy Haggstrom
• Breast cancer risk factors – translating the evidence - Vivienne Milch
• The use of trimethoprim/sulfamethoxazole for prevention of melioidosis in cancer patients treated in the Top End of the Northern Territory of Australia: a retrospective audit of clinical practice and outcomes over a single ‘wet’ season - Kristin Hsu
• A Retrospective Audit on the adherence to Hepatitis B Screening in Adjuvant Chemotherapy for Breast and Colon Cancer  - Jared Mathai
• Risk factors for endometrial cancer – summarising and communicating the evidence - Vivienne Milch
• Effect of body mass index on survival outcomes of patients with HER-2 positive advanced breast cancer - Natansh D Modi
• Changing demographics and patterns of care in oropharyngeal cancer: a statewide population-based analysis - Theresa Negrello
• TMEM and Mena^calc: new prognostic markers for breast cancer - Thomas E Rohan
• Psychological well-being of more than seven years’ endometrial cancer survivors - Saira SS Sanjida
• The effects of beta-blocker use in HER2- positive advanced breast cancer and implications on survival outcomes - Eugene Tan
• Questionnaire to uncover population characteristics of pre-treated metastatic Gastric cancer patients in Australia. - Guy Tancock
• Epidemiology of sepsis in cancer patients in Victoria, Australia - A population-based study using linked data - Luc te Marvelde
• Cancer in Queensland adults aged 65+ years: trends in incidence, mortality and survival - Nathan Dunn
• Demographics and Tumour Characteristics of Metastatic Lung Cancer: Central Queensland Experience 2016-2019 - Hyung Sun Yoo
• It Feels Like Home - The Chemo Day-Unit of the Future - Julie Adams
• Patient Safety Where no Standards Exist - Julie Adams
• Perceived benefits and limitations of using patient-reported outcome measures in clinical practice with individual patients: A systematic review of qualitative studies. - Rachel Campbell
• What are the benefits of placing Cancer Pharmacists in Cancer Outpatient clinics? - Christine V Carrington
• A Retrospective Audit of Male Prisoners Referred to Cancer Services at Prince of Wales Hospital. - Kim KC Chah
• Timeliness of lung cancer treatment utilizing the rapid access lung cancer clinic in a regional Australian hospital. - Hieu Chau
• Understanding cancer-related communication and expectations of patients and family members in an Indian hospital: A qualitative study - Shweta K Chawak
• Development of a question prompt list for Indian cancer patients and their primary family carers - Shweta K Chawak
• Development and feasibility of measuring quality indicators using lung cancer multidisciplinary team meeting data - Kim-Lin Chiew
• Ascertaining barriers faced with accurate medication history takings for oncology patients transferred from another cancer centre - Xue Zhen XC Choo
• Inattentional Blindness and Other Lessons Learned from Exploring the Experiences of Pharmacists in Cancer Care - Lauren Cortis
• 99 Problems and the Medicines Are One: Experiences of People Managing a Pre-Existing Chronic Condition through Cancer Diagnosis and Treatment - Lauren Cortis
• Outcomes following radical cystectomy for patients diagnosed with bladder cancer in Queensland - Geoff Coughlin
• Preliminary investigation into the provision of clinical pharmacist services within the radiation oncology setting. - Shana L Edwards
• Increasing Access to Clinical Trials for Adolescents and Young Adults (AYA) with Cancer - Justine Ellis
• Patient reported problems during implementation of the Clinical Pathway for the Screening, Assessment and Management of Anxiety and Depression in Adult Cancer Patients (ADAPT CP). An interim analysis. - Mona Faris
• Having breast reconstruction post-mastectomy: Barriers and facilitators reported by Vietnamese- versus English-speaking women with breast cancer - Afaf Girgis
• Staged Implementation of the Victorian cancer multidisciplinary team meeting quality framework: establishing a baseline measurement of MDMs. - Anna Hedigan
• Multidisciplinary approach to implementation of safe handling procedure for hazardous drugs in the cancer setting. - Bishma Jayathilaka
• Trade-offs of adjuvant immunotherapy in stage-III melanoma – a clinicians’ view? - Martin R Stockler
• Patient Navigation in Cancer Care: An alternative workforce model responding to the complexities of the cancer ecosystem - Geraldine McDonald
• Development of a culturally adapted interactive online Malnutrition Screening Tool - Jenelle Loeliger
• ImpleMenting the Aspirin Guidelines Into Clinical care (I-MAGIC project) - Shakira R Milton
• The failure to follow up abnormal test results associated with undiagnosed prevalent cancer in primary care: a systematic review protocol - Jon Emery
• The prevalence of abnormal test results associated with undiagnosed prevalent cancer and their follow-up in Australian primary care: a secondary analysis of the NPS MedicineInsight dataset - Jon Emery
• Improving communication between health professionals and Aboriginal and Torres Strait Islander people who have been diagnosed with cancer - Ian Olver
• Can delayed screening disrupt routine (over)use of the prostate screening test? Testing a new strategy - Kristen Pickles
• Population-wide review of head and neck cancer treatment and mortality; Queensland experience - Theresa Negrello
• Reasons for non-attendance in an acute oncology inpatient exercise class - Sharni Quinn
• Peter MacCallum Cancer Centre Prehabilitation Program: Evaluation of Expanded Allied Health Service - Sharni Quinn
• “Use our words for change”: Developing and implementing culturally appropriate patient experience surveys for Australian Aboriginal and Torres Strait Islander people. - Eli Ristevski
• Barriers and facilitators to implementing a cancer survivorship model of care in a rural area. - Eli Ristevski
• Barriers and enablers to implementing patient-reported outcome measures (PROMs) in clinical settings: a meta-review of reviews - Claudia Rutherford
• Parenteral cancer medicines reassignment- should pharmacies be reimbursed for their staff time? A preliminary analysis - Marissa I Ryan
• Multi-disciplinary team meetings and its influence on breast cancer management in a tertiary hospital in Sydney, NSW - Jesmin Shafiq
• Translation of Lung Multidisciplinary Team Meeting Recommendations into Clinical Practice - Jesmin Shafiq
• To evaluate the impact and possibility of home administration subcutaneous azacitidine at a rural cancer treatment centre - Penelope PT Tanner
• Pilot study: Home administration of subcutaneous bortezomib at a rural cancer treatment centre - Penelope PT Tanner
• Our experience of Nursing/Allied Health practitioner led Geriatric Screening and Assessment of elderly oncology patients – A highly accessible model of care - Darshit A Thaker
• Is there a need for change in survivorship care?: A qualitative exploration of cancer survivor experiences and ongoing needs at the Sydney Cancer Survivorship Centre Clinic - Janette L Vardy
• Single Fraction Palliative Radiotherapy for Bone Metastases - Laxmi Vasireddi
• Investigating the system impact of reporting multidisciplinary care measures for cancer services in NSW - Kahren M White
• Patterns of care and variation for women with ovarian cancer in NSW using the national optimal cancer care pathway for ovarian cancer - Kahren M White
• Global demands for chemotherapy, HER-2 and endocrine therapy for breast cancer using NCCN resource stratified guidelines - Brooke E Wilson
• Survivorship Needs of an Elderly Population with Cancer - a Pilot Study of Care Coordination - Zee Wan Wong
• Australian Oncofertility, A Changing Landscape. - Franca Agresta
• Metropolitan/Regional Engagement – Working towards sustainable professional networks. A LMICS and WCMICS Initiative - Christopher Caudle
• Royal Brisbane Medical Oncology Clinic Activity Review - Anna Kuchel
• Redesign of dietetic service in the ambulatory oncology setting – a trial to optimise patient centred care - Stephanie Labourne
• Implementation of a Lung Cancer Care Plan at Eastern Health - Angus Taylor
• Optimising patient information uptake - Geraldine McDonald
• Improving the timelines of the oesophago-gastric cancer patient journey through a regional Victorian hospital - Michael Leach
• An observational audit in an aseptic compounding facility: investigating latent errors in manufacturing cancer medicines  - Marissa I Ryan
• An International Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck - Junya Eguchi
• XENERA™-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement - Dennis Chin-Lun Huang
• Exercise and cancer-related cognitive impairment: a study protocol  - Eliza Keating
• A psychosexual intervention for couples within the first year post-allogeneic haematopoietic stem cell transplantation: A pilot study - Brindha Pillay
• Combination of Avelumab with Peptide Receptor Radionuclide Therapy (PRRT) or Conventional Fractionated Radiotherapy (RT) in Metastatic Merkel Cell Carcinoma (mMCC) [GoTHAM study] - Shahneen Sandhu
• SOLACE2: A phase II randomised trial of immune priming by olaparib-cyclophosphamide prior to olaparib-durvalumab in asymptomatic, platinum-sensitive recurrent ovarian cancer - Stephanie Hollis
• A randomised, double-blind, placebo-controlled, multi-institutional phase II study of adjuvant anti-PD-1 in patients with stage I-III Merkel cell carcinoma [I-MAT Study] - Junya Eguchi
• Developing a framework for registry-based randomised controlled trials in oncology - Belinda Lee
• Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC) - F Parnis
• Patient Adherence and Understanding of Calcium and Vitamin D Supplements in the Setting of Denosumab Therapy - Kate Kim

• The Patient Perspective  - Shona Edwards
• Exercise and nutrition to treat adverse musculoskeletal effects of hormone therapy in prostate cancer - Steve Fraser
• The cardio-oncology burden is ever-present, so how can we affordably & feasibly assess cardiorespiratory fitness in every patient - David Mizrahi
• It’s not all face to face: digital delivery of exercise oncology  - Michael Marthick

5:15 PM Panel Discussion 

• Maximising Cure while Minimising Treatment in Testicular Cancer - Andrew Weickhardt
• What are the psychosocial challenges facing testicular cancer survivors and how can technology help to address them?  - Ben Smith
• Endocrine consequences of treatment: hypogonadism  - Ada Cheung
• Surgical advances: Robotic retro peritoneal lymph node dissection  - Nari Ahmadi
• 50/50 - Comedian Michael Shafar's reflections on being diagnosed with testicular cancer - Michael N Shafar

• International volunteering through ASCO – a Vietnam experience  - David Goldstein
• Developing Oncology Services in Johannes Hospital, Kupang, West Timor  - Chris Karapetis
• The APROSIG-National Cancer Centre collaboration: expanding access to radiation therapy in Cambodia  - Mei Ling Yap
• DFAT Pacific Islands Program: Building Capacity and Capability of an Oncology Unit in the Solomon Islands - Desmond Yip
• Developing a model for safe cytotoxic administration in the Solomon Islands  - Wendy Spencer

5:15PM Panel Discussion 

Chair: Professor Gerald Fogarty,

University of Technology, Sydney & Director, Radiation Oncology, Genesis Cancer Care

Speakers: